TY - JOUR
T1 - Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake
T2 - A randomized, cross-over study
AU - DeFronzo, Ralph A.
AU - Okerson, Ted
AU - Viswanathan, Prabhakar
AU - Guan, Xuesong
AU - Holcombe, John H.
AU - MacConell, Leigh
N1 - Funding Information:
Declaration of interest: This study was funded by Amylin Pharmaceuticals, Inc and Eli Lilly and Company. R.A.D. holds research grants with Amylin, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer, and Takeda. He serves on speaker bureaus for Amylin and Takeda and sits on advisory boards for Amylin, Bristol-Myers Squibb, Novartis, Pfizer, Takeda, Johnson and Johnson, and ISIS. T.O., P.V., X.G., and L.M. are employees and stockholders of Amylin Pharmaceuticals, Inc. J.H. is an employee and stockholder of Eli Lilly and Company. Amylin Pharmaceuticals, Inc. has a global agreement with Eli Lilly and Company to collaborate on the development and commercialization of exenatide. The authors thank Dr. Anthony Stonehouse, an employee of Amylin Pharmaceuticals, for his assistance in the preparation of this article.
PY - 2008/10
Y1 - 2008/10
N2 - Background: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients. Methods: This double-blind, randomized cross-over, multi-center study was conducted in metformin-treated T2D patients: 54% female; BMI: 33 ± 5 kg/m2; HbA1c: 8.5 ± 1.2%; 2-h PPG: 245 ± 65 mg/dL. Patients received exenatide (5 μg BID for 1 week, then 10 μg BID for 1 week) or sitagliptin (100 mg QAM) for 2 weeks. After 2 weeks, patients crossed-over to the alternate therapy. Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients). Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581). Results: After 2 weeks of therapy, 2-h PPG was lower with exenatide versus sitagliptin: 133 ± 6 mg/dL versus 208 ± 6 mg/dL, p < 0.0001 (evaluable, N= 61). Switching from exenatide to sitagliptin increased 2-h PPG by +73 ± 11 mg/dL, while switching from sitagliptin to exenatide further reduced 2-h PPG by - 76 ± 10 mg/dL. Postprandial glucose parameters (AUC, Cave, Cmax) were lower with exenatide than sitagliptin (p<0.0001). Reduction in fasting glucose was similar with exenatide and sitagliptin (-15 ± 4 mg/dL vs. -19 ± 4 mg/dL, p=0,3234). Compared to sitagliptin, exenatide improved the insulinogenic index of insulin secretion (ratio exenatide to sitagliptin: 1.50 ± 0.26, p=0.0239), reduced postprandial glucagon (AUC ratio exenatide to sitagliptin: 0.88 ± 0.03, p=0.0011), reduced postprandial triglycerides (AUC ratio exenatide to sitagliptin: 0.90 ± 0.04, p=0.0118), and slowed gastric emptying (acetaminophen AUC ratio exenatide to sitagliptin: 0.56 ± 0.05, p<0.0001). Exenatide reduced total caloric intake compared to sitagliptin (-134 ± 97 kcal vs. +130 ± 97 kcal, p=0.0227, N= 25). Common adverse events with both treatments were mild to moderate in intensity and gastrointestinal in nature. Conclusions: Although this study was limited by a 2-week duration of exposure, these data demonstrate that, exenatide had: (i) a greater effect than sitagliptin to lower postprandial glucose and (ii) a more potent effect to increase insulin secretion and reduce postprandial glucagon secretion in T2D patients. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. These key findings differentiate the therapeutic actions of the two incretin-based approaches, and may have meaningful clinical implications.
AB - Background: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients. Methods: This double-blind, randomized cross-over, multi-center study was conducted in metformin-treated T2D patients: 54% female; BMI: 33 ± 5 kg/m2; HbA1c: 8.5 ± 1.2%; 2-h PPG: 245 ± 65 mg/dL. Patients received exenatide (5 μg BID for 1 week, then 10 μg BID for 1 week) or sitagliptin (100 mg QAM) for 2 weeks. After 2 weeks, patients crossed-over to the alternate therapy. Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients). Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581). Results: After 2 weeks of therapy, 2-h PPG was lower with exenatide versus sitagliptin: 133 ± 6 mg/dL versus 208 ± 6 mg/dL, p < 0.0001 (evaluable, N= 61). Switching from exenatide to sitagliptin increased 2-h PPG by +73 ± 11 mg/dL, while switching from sitagliptin to exenatide further reduced 2-h PPG by - 76 ± 10 mg/dL. Postprandial glucose parameters (AUC, Cave, Cmax) were lower with exenatide than sitagliptin (p<0.0001). Reduction in fasting glucose was similar with exenatide and sitagliptin (-15 ± 4 mg/dL vs. -19 ± 4 mg/dL, p=0,3234). Compared to sitagliptin, exenatide improved the insulinogenic index of insulin secretion (ratio exenatide to sitagliptin: 1.50 ± 0.26, p=0.0239), reduced postprandial glucagon (AUC ratio exenatide to sitagliptin: 0.88 ± 0.03, p=0.0011), reduced postprandial triglycerides (AUC ratio exenatide to sitagliptin: 0.90 ± 0.04, p=0.0118), and slowed gastric emptying (acetaminophen AUC ratio exenatide to sitagliptin: 0.56 ± 0.05, p<0.0001). Exenatide reduced total caloric intake compared to sitagliptin (-134 ± 97 kcal vs. +130 ± 97 kcal, p=0.0227, N= 25). Common adverse events with both treatments were mild to moderate in intensity and gastrointestinal in nature. Conclusions: Although this study was limited by a 2-week duration of exposure, these data demonstrate that, exenatide had: (i) a greater effect than sitagliptin to lower postprandial glucose and (ii) a more potent effect to increase insulin secretion and reduce postprandial glucagon secretion in T2D patients. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. These key findings differentiate the therapeutic actions of the two incretin-based approaches, and may have meaningful clinical implications.
KW - DPP-4 inhibitor
KW - Exenatide
KW - GLP-1
KW - Glycemia
KW - Incretin mimetic
KW - Postprandial glucose
KW - Sitagliptin
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=55549136417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55549136417&partnerID=8YFLogxK
U2 - 10.1185/03007990802418851
DO - 10.1185/03007990802418851
M3 - Article
C2 - 18786299
AN - SCOPUS:55549136417
SN - 0300-7995
VL - 24
SP - 2943
EP - 2952
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 10
ER -